What are the specific targeted therapy options for patients with BRAF-mutant melanoma, and how do they work...

According to the NCCN Guidelines for Patients: Melanoma, there are several targeted therapy options for patients with BRAF-mutant melanoma:

1. Dabrafenib or trametinib:
   • The NCCN states that "One such neoadjuvant treatment is dabrafenib or trametinib for people who have BRAF V600 mutation." (NCCN Guidelines for Patients: Melanoma, p. 56)
   • These targeted therapies work by inhibiting the BRAF and MEK proteins, which are part of the MAPK signaling pathway that drives melanoma cell growth and proliferation.

In contrast to traditional chemotherapy, the NCCN notes that targeted therapies like dabrafenib and trametinib "work better and may be safer than other therapies" for BRAF-mutant melanoma. (NCCN Guidelines for Patients: Melanoma, p. 56)

The key differences are:

• Targeted therapies specifically target the genetic mutations driving the cancer, whereas chemotherapy drugs broadly target rapidly dividing cells.
• Targeted therapies tend to have fewer systemic side effects compared to the non-specific toxicity of chemotherapy drugs.
• Targeted therapies can be more effective at shrinking tumors and delaying disease progression in patients with BRAF-mutant melanoma.

The NCCN recommends considering targeted therapy combinations, such as dabrafenib plus trametinib, as a preferred neoadjuvant (pre-surgical) treatment option for patients with resectable stage III BRAF-mutant melanoma. (NCCN Guidelines for Patients: Melanoma, p. 56)